Aprea

What Aprea does

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that target the DNA damage response (DDR) pathway in cancer. The company's pipeline is anchored on synthetic-lethality approaches, with two lead clinical-stage assets: APR-1051, an orally bioavailable WEE1 inhibitor positioned for tumors harboring CCNE1 amplification and other DDR vulnerabilities, and ATRN-119, an ATR inhibitor originating from the May 2022 acquisition of Atrin Pharmaceuticals and aimed at tumors with homologous recombination repair deficiencies (e.g., ARID1A mutations). The company's earlier eprenetapopt (APR-246) program, a first-in-class small-molecule p53 reactivator, has been deprioritized and placed on hold, while a next-generation p53 reactivator (APR-548) remains in earlier-stage development. Aprea is headquartered in Doylestown, Pennsylvania, with research operations in Stockholm, Sweden, and trades on NASDAQ under the ticker APRE following its October 2019 IPO.

The company's business model is that of a traditional clinical-stage biotech: it generates no product revenue and instead funds operations through equity financings. As of March 31, 2026, Aprea reported approximately $46.5 million in cash and guided a runway into Q1 2028, supported in part by a $30 million financing led by Soleus Capital in March 2026. The organization operates with a lean headcount of 1-10 employees, reflecting an outsourced/virtual clinical-development model typical of small-cap oncology biotechs. Aprea does not yet have a commercialization infrastructure, and its future revenue mechanics will depend on either direct product launch, partnership/out-licensing of clinical-stage assets to larger pharmaceutical companies, or both. Its customer base, in the commercial sense, does not yet exist; its primary economic counterparties today are equity capital providers and clinical-trial investigators.

Strategically, Aprea is positioned as a focused pure-play in DDR-targeted oncology, with a deliberate narrowing of scope (deprioritization of APR-246) and a concentration of capital on its WEE1 and ATR programs. The dual-mechanism platform (WEE1 + ATR) provides combinatorial optionality — both targets are clinically validated in DDR and both can be developed as monotherapy or in combination with chemotherapy, PARP inhibitors, or immunotherapy. The company's competitive set includes larger oncology players (e.g., developers of adavosertib follow-ons, ceralasertib-class ATR inhibitors), and its differentiation rests on clinical positioning in genetically defined patient populations and the optionality of its dual-asset DDR platform.

Name

Aprea

Legal name

Aprea Therapeutics, Inc.

Website

https://aprea.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing DNA damage response inhibitors — including WEE1 (APR-1051) and ATR (ATRN-119) programs — for genetically defined cancer populations. Headquartered in Doylestown, PA with R&D in Stockholm, the company trades on NASDAQ as APRE.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Precision oncology therapeutics
• DNA damage response inhibitors
• Small molecule cancer drugs
• Targeted cancer therapy
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing DDR-targeted cancer therapeutics with lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor) in clinical development. No commercialized products generating revenue currently.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing DNA Damage Response (DDR)-targeted small molecule inhibitors for precision oncology. Its lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an oral ATR inhibitor, both in Phase 1 clinical trials for advanced solid tumors. The company also develops p53 reactivators (eprenetapopt/APR-246 and APR-548) for hematologic malignancies such as MDS and AML, targeting cancers harboring specific DDR-related genetic mutations including TP53 and PPP2R1A.

Product overview

Aprea Therapeutics is a clinical-stage precision medicine oncology company developing DDR-targeted small molecule therapeutics designed to exploit cancer-related genetic mutations. The company's pipeline includes two lead clinical-stage programs: APR-1051, a WEE1 kinase inhibitor in Phase 1 for advanced solid tumors (endometrial, uterine serous carcinoma, ovarian cancer); and ATRN-119, an oral ATR inhibitor in Phase 1/2a for advanced solid tumors. The company previously developed p53 reactivators including eprenetapopt (APR-246, on clinical hold) for hematologic malignancies and is advancing next-generation oral p53 reactivator APR-548 in Phase 1 for MDS. The company relocated headquarters to Doylestown, PA while maintaining research operations in Stockholm, Sweden.

Differentiator

Problem solved

Functional benefit

Products and services

• APR-1051 A selective WEE1 kinase inhibitor administered orally, currently in Phase 1 clinical development (ACESOT-1051 trial) for advanced solid tumors. Demonstrated 15% tumor burden reduction and disease stabilization in patients, with two partial responses observed in endometrial cancer patients at the 220mg dose level. Being developed for uterine serous carcinoma and platinum-resistant ovarian cancer indications.
• ATRN-119 An oral ATR inhibitor in Phase 1/2a dose-escalation study (ABOYA-119) for advanced solid tumors. The recommended Phase 2 dose (RP2D) of 1,100 mg once daily has been established. Development focus is shifting toward combination therapy approaches with DNA-damaging agents, radiation therapy, antibody-drug conjugates (ADCs), and checkpoint inhibitors.
• Eprenetapopt (APR-246)
• APR-548

Quantifiable outcome

• APR-1051 demonstrated 15% tumor burden reduction and disease stabilization in patients
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality and DDR-targeted therapies (ATR, PKMYT1). Directly comparable to Aprea in mechanism, target patient population (DDR-mutated cancers), and clinical-stage profile.
• Tango Therapeutics: Clinical-stage synthetic lethality and DDR-focused oncology company developing PRMT5 and other DDR inhibitors. Shares Aprea's precision oncology, DDR-mutation targeting approach, and clinical-stage development profile.
• IDEAYA Biosciences: Clinical-stage precision oncology company developing synthetic lethality and DDR-targeted therapies including MAT2A and PARG inhibitors. Comparable technology platform, similar oncology indications, and clinical-stage profile.
• Zentalis Pharmaceuticals: Clinical-stage oncology company developing WEE1 inhibitor azenosertib and other DDR-targeted small molecules. Most direct mechanistic competitor to Aprea's APR-1051, with overlapping indications in gynecologic cancers.

Emerging players

• Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Comparable in precision oncology approach and small-molecule inhibitor technology, but targets different oncogenic mutations than Aprea's DDR focus.
• Arcus Biosciences: Clinical-stage immuno-oncology company with DDR combination strategies (TIGIT, adenosine, and DDR inhibitors). Comparable in combination therapy approaches for checkpoint inhibition and DNA-damaging agent combos relevant to ATRN-119.
• Schrodinger: Computational drug discovery company with clinical-stage oncology pipeline including DNA damage response inhibitors. Comparable in small-molecule precision oncology drug development, though Aprea is more focused on DDR specifically.
• Foghorn Therapeutics: Clinical-stage oncology company developing chromatin biology-based therapeutics. Comparable as a clinical-stage precision oncology company with small molecule platform, but focused on different mechanistic targets (chromatin regulation) than DDR.
• Halda Therapeutics: Clinical-stage oncology company developing targeted protein degrader therapeutics. Connected to Aprea through former CEO Christian Schade, who led both companies, reflecting similar stage of clinical development and oncology focus.

Broad incumbents

• Exelixis: Established commercial-stage oncology company with kinase inhibitor portfolio (cabozantinib) and pipeline including DDR targets. Comparable in oncology small-molecule space, but significantly larger, more diversified, and with revenue from marketed products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aprea_asiapac
• Facebookfacebook.com/apreatherapeutics
• LinkedInlinkedin.com/company/aprea-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds11 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aprea